Uses
USE(S) helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Source: US FDA prescribing information
Molecule
Guaifenesin
Expectorant
Available on request
- Presentations
- 1
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Guaifenesin is an expectorant. It is available as extended-release tablets for oral use. MedsAcross supplies Guaifenesin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Expectorant, Decreased Respiratory Secretion Viscosity, Increased Respiratory Secretions
- ATC classification
- R05CA03 Guaifenesin · Mucokinetic
- US FDA first approval
- 12 July 2002
- EU status
- Not recorded
- Orphan designation
- Not recorded
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Oral
- Dosage forms
- Extended-release tablet
- Identifiers
- UNII 495W7451VQRxCUI 5032CAS 93-14-1DrugBank DB00874Q420682
Clinical information
From the regulator-approved product information. Each section names its source.
Dosing overview
DIRECTIONS do not crush, chew, or break tablet take with a full glass of water this product can be administered without regard for the timing of meals adults and children 12 years of age and over: 1 or 2 tablets every 12 hours. Do not exceed 4 tablets in 24 hours. children under 12 years of age: do not use
Source: US FDA prescribing information
Warnings and precautions
WARNING.
Source: US FDA prescribing information
Storage
OTHER INFORMATION tamper evident: do not use if seal on the bottle printed "SEALED for YOU PROTECTION" is broken or missing. store between 20 to 25°C (68 to 77°F)
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
1 presentations of Guaifenesin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Mucus Relief 600 mg extended-release tabletOral | Bryant Ranch Prepack | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 12 July 2002 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions
Conditions linked to Guaifenesin in public data. This is not a list of approved uses, see the clinical information.
Questions and answers
Is Guaifenesin available for export from India?
Yes, on request. MedsAcross lists 1 presentations of Guaifenesin and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Guaifenesin have?
The catalogue lists 1 brand names for Guaifenesin, including Mucus Relief.
Is Guaifenesin approved by the US FDA?
Yes. The US FDA first approved Guaifenesin on 12 July 2002, according to Drugs@FDA.
Does Guaifenesin need cold chain shipping?
No listed presentation of Guaifenesin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Guaifenesin in?
Guaifenesin is classified under ATC code R05CA03 (Guaifenesin).
References
- Mucus Relief prescribing information (Bryant Ranch Prepack). U.S. National Library of Medicine, DailyMed. Retrieved 2 June 2025
Request Guaifenesin for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.